Manhattan Scientifics, Inc. (MHTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Manhattan Scientifics, Inc. (MHTX) trades at $0.00 with AI Score 46/100 (Grade C). Manhattan Scientifics, Inc. operates as an innovation hub focused on advancing nanotechnology and nanomedicine to enhance human life in the U. S. Market cap: $11,186, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for MHTX: MHTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MHTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MHTX: the 1 perspectives are evenly split.
How is this calculated? →Manhattan Scientifics, Inc. (MHTX) Healthcare & Pipeline Overview
Manhattan Scientifics, Inc. (MHTX) functions as an innovation hub, specializing in the advancement and market introduction of nanotechnology and nanomedicine technologies across the United States. Established in 1992, the company focuses on developing disruptive solutions aimed at enhancing human life, positioning itself within the healthcare sector as an early-stage technology incubator.
What Is the Investment Thesis for MHTX?
Manhattan Scientifics, Inc. (MHTX) presents an investment profile centered on its role as an innovation hub and technology incubator, specializing in the advancement of nanotechnology and nanomedicine. The core value driver lies in its portfolio of early-stage, potentially disruptive technologies, offering investors exposure to high-growth sectors within healthcare. The company's strategy involves identifying and commercializing these nascent innovations, aiming to enhance human life across the United States. However, the investment thesis is significantly shaped by MHTX's operational characteristics and market listing. With a reported market capitalization of 11K and a high beta of 9.04, the stock exhibits extreme volatility and a highly speculative nature, indicative of its early development stage and limited operational scale, currently with one employee. As an OTC Other listed company, MHTX faces inherent risks including limited regulatory oversight and potential liquidity challenges, which necessitate close monitoring of its ability to secure adequate funding and successfully transition its technologies from development to commercialization. Future growth catalysts would likely stem from successful clinical trials, regulatory approvals, or strategic partnerships for its incubated technologies, while the primary risk remains the inherent uncertainty of early-stage technology commercialization and funding.
Based on FMP financials and quantitative analysis
MHTX Key Highlights
- Operates as an innovation hub focused on nanotechnology and nanomedicine, targeting high-growth sectors within healthcare.
- Maintains a lean operational structure with 1 employee, indicating a focus on incubation and external partnerships.
- Exhibits a market capitalization of 11K, reflecting its early-stage development and limited market valuation.
- Demonstrates high market volatility with a beta of 9.04, signifying significant price fluctuations relative to the broader market.
- Trades on the OTC Other market, implying reduced regulatory oversight and potential liquidity challenges for investors.
Who Are MHTX's Competitors?
MHTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MHTX's Key Strengths?
- Specialized focus on high-growth nanotechnology and nanomedicine sectors.
- Innovation hub model allows for agile development of disruptive technologies.
- Portfolio of early-stage technologies offers exposure to future market leaders.
- Lean operational structure with 1 employee, potentially minimizing overhead.
What Are MHTX's Weaknesses?
- Limited operational scale with only one employee.
- Market capitalization of 11K indicates very early stage or minimal valuation.
- High beta (9.04) suggests extreme price volatility and speculative nature.
- Reliance on external funding for technology commercialization.
What Could Drive MHTX Stock Higher?
- Successful securing of additional funding for technology development and commercialization efforts.
- Achievement of key milestones in the development or testing of its incubated nanotechnology solutions.
- Formation of strategic partnerships or licensing agreements for its intellectual property in nanomedicine.
- Positive regulatory developments or approvals for any of its early-stage medical technologies.
What Are the Key Risks for MHTX?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant liquidity challenges and limited regulatory oversight due to OTC Other listing.
- High operational risk associated with early-stage technology commercialization and market adoption uncertainty.
- Inability to secure sufficient funding to advance its nanotechnology and nanomedicine projects.
- Intense competition from larger, better-funded companies in the healthcare and medical device sectors.
- Failure to achieve necessary regulatory approvals for its medical technologies.
What Are the Growth Opportunities for MHTX?
- Advancements in Nanomedicine for Diagnostics: The global nanomedicine market is experiencing robust growth, with diagnostics being a key segment. Manhattan Scientifics, Inc.'s focus on nanomedicine positions it to potentially capitalize on the development of highly sensitive and early-stage diagnostic tools. Nanoparticle-based diagnostics offer advantages such as enhanced imaging contrast, targeted delivery of diagnostic agents, and improved detection of biomarkers for diseases like cancer and neurological disorders. Successful incubation and commercialization of such a technology could tap into a market projected to reach significant valuations, driven by increasing demand for precision medicine and preventative healthcare.
- Therapeutic Applications of Nanotechnology: Nanotechnology holds immense promise in developing novel therapeutic solutions, particularly in targeted drug delivery. By encapsulating drugs within nanoparticles, treatments can be delivered more precisely to diseased cells, minimizing side effects and improving efficacy. This approach is particularly relevant for oncology and chronic disease management. Manhattan Scientifics, Inc.'s commitment to nanomedicine allows it to explore and nurture technologies that could disrupt traditional drug delivery methods, addressing a substantial unmet need in the pharmaceutical market. The potential market size for targeted nanotherapeutics is considerable and growing.
- Development of Novel Medical Devices: Beyond drug delivery, nanotechnology is integral to the creation of next-generation medical devices, including biosensors, smart implants, and advanced surgical tools. These devices can offer enhanced functionality, miniaturization, and biocompatibility. As an innovation hub, MHTX is positioned to identify and support the development of such devices that leverage nanoscale engineering principles. Successful commercialization of a breakthrough medical device could secure a significant share in specific niches of the medical device market, which is constantly seeking more effective and less invasive solutions for patient care.
- Strategic Partnerships and Licensing: Given its model as an innovation hub and incubator with a lean operational structure (1 employee), a significant growth opportunity for Manhattan Scientifics, Inc. lies in forming strategic partnerships with larger pharmaceutical companies, medical device manufacturers, or research institutions. These collaborations could provide necessary funding, expertise, and market access for its early-stage technologies. Licensing agreements for its intellectual property (IP) could generate revenue without requiring extensive capital expenditure for manufacturing or distribution, allowing MHTX to focus on its core incubation activities and de-risk its portfolio.
- Expansion into Energy-Related Nanotechnology: While primarily focused on healthcare, the AI Insight mentions "energy-related applications" as another area of focus. This diversification represents a potential growth opportunity. Nanotechnology can significantly impact energy efficiency, storage, and generation, through advancements in solar cells, batteries, and catalysts. If MHTX successfully incubates and commercializes a technology in this sector, it could tap into a vast and growing market driven by global demand for sustainable and efficient energy solutions, diversifying its revenue streams beyond healthcare and leveraging its core nanotechnology expertise.
What Opportunities Does MHTX Have?
- Growing global demand for advanced diagnostic and therapeutic solutions in healthcare.
- Potential for strategic partnerships or licensing agreements with larger industry players.
- Diversification into energy-related nanotechnology applications.
- Successful commercialization of a breakthrough technology.
What Threats Does MHTX Face?
- Significant regulatory hurdles and lengthy approval processes in healthcare.
- Intense competition from well-funded research institutions and large corporations.
- Challenges in securing adequate funding for R&D and commercialization.
- High risk of technology failure or market adoption issues for early-stage innovations.
What Are MHTX's Competitive Advantages?
- Specialized focus and expertise in nanotechnology and nanomedicine.
- Portfolio of early-stage, potentially disruptive technologies.
- Agile innovation hub model for rapid development and commercialization.
- Potential for strong intellectual property derived from incubated technologies.
What Does MHTX Do?
Manhattan Scientifics, Inc., established in 1992 and formerly known as Grand Enterprises, Inc., operates as a dedicated innovation hub headquartered in New York City, United States. The company's core mission revolves around the advancement and market introduction of pioneering technologies specifically designed to enhance human life. Its strategic focus is intensely concentrated within the burgeoning fields of nanotechnology and nanomedicine, areas recognized for their potential to revolutionize various aspects of healthcare and beyond. As a technology incubator, Manhattan Scientifics, Inc. strategically identifies, develops, and seeks to commercialize potentially disruptive technologies. This operational model positions the company at the forefront of early-stage technological innovation, aiming to bring groundbreaking scientific discoveries from the laboratory to practical application. The firm's efforts are geared towards building a portfolio of such nascent technologies, thereby offering exposure to high-growth sectors that are often characterized by significant research and development requirements and long commercialization cycles. With a lean operational structure, evidenced by its single employee, the company's approach emphasizes external partnerships and collaborative development to leverage specialized expertise and resources. Manhattan Scientifics, Inc. aims to play a pivotal role in translating complex scientific concepts into tangible products or services that can address unmet needs and improve quality of life across the United States. Its historical evolution from Grand Enterprises, Inc. to its current identity reflects a strategic pivot towards specialized high-tech sectors, underscoring a commitment to innovation-driven growth within the healthcare technology landscape. The company's model as an innovation hub suggests a focus on nurturing and scaling technologies rather than direct large-scale manufacturing or service delivery, relying on the successful commercialization of its intellectual property or incubated ventures.
What Products and Services Does MHTX Offer?
- Operates as an innovation hub and technology incubator.
- Focuses on advancing and introducing technologies to enhance human life.
- Specializes in the fields of nanotechnology and nanomedicine.
- Identifies and develops potentially disruptive early-stage technologies.
- Aims to commercialize innovations in high-growth sectors.
- Seeks to bring scientific discoveries from research to practical application.
- Headquartered in New York City, serving the United States market.
How Does MHTX Make Money?
- Incubating and developing early-stage technologies in nanotechnology and nanomedicine.
- Commercializing these technologies through licensing, partnerships, or spin-offs.
- Generating revenue from successful market introduction of innovative products or services.
- Potentially through intellectual property sales or royalty agreements.
What Industry Does MHTX Operate In?
Manhattan Scientifics, Inc. operates within the dynamic and rapidly evolving healthcare sector, specifically targeting the Medical - Devices industry through its focus on nanotechnology and nanomedicine. The broader market for nanomedicine is characterized by significant growth potential, driven by advancements in drug delivery systems, diagnostics, and therapeutic applications. This field is projected to expand as research yields more practical applications for nanoscale materials in biological systems. MHTX positions itself not as a direct manufacturer or service provider, but as an innovation hub and technology incubator. This model places it within a competitive landscape populated by both specialized nanotechnology firms and larger pharmaceutical or medical device companies with dedicated R&D arms exploring similar frontiers. The company's strategy is to identify and nurture early-stage technologies, aiming to capture value from their eventual commercialization. Its success is intrinsically linked to the broader trends in scientific discovery and the ability to navigate complex regulatory pathways inherent in the healthcare and medical device industries.
Who Are MHTX's Key Customers?
- Pharmaceutical companies seeking advanced drug delivery systems.
- Medical device manufacturers looking for innovative components or products.
- Healthcare providers adopting new diagnostic tools or therapies.
- Potentially, end-users or patients benefiting from enhanced medical solutions.
How Manhattan Scientifics, Inc. Is Valued
Manhattan Scientifics, Inc. carries a market capitalization of 11K, placing it in the micro-cap category. Relative to its peer group, MHTX's quantitative score of 46/100 is below the peer average of 69/100.
Company Profile
Manhattan Scientifics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Emmanuel Tsoupanarias. MHTX has traded publicly since 1998.
ROE 67%Key Financial Metrics
Return on equity for Manhattan Scientifics, Inc. stands at 66.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Manhattan Scientifics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
MHTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized focus on high-growth nanotechnology and nanomedicine sectors.
- Innovation hub model allows for agile development of disruptive technologies.
- Portfolio of early-stage technologies offers exposure to future market leaders.
- Lean operational structure with 1 employee, potentially minimizing overhead.
Bear Case
- Limited operational scale with only one employee.
- Market capitalization of 11K indicates very early stage or minimal valuation.
- High beta (9.04) suggests extreme price volatility and speculative nature.
- Reliance on external funding for technology commercialization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MHTX Latest News
No recent news available for MHTX.
MHTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MHTX.
Price Targets
Wall Street price target analysis for MHTX.
MHTX MoonshotScore
What does this score mean?
The MoonshotScore rates MHTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Emmanuel Tsoupanarias
CEO
Unknown. Information regarding Emmanuel Tsoupanarias's specific career history, educational background, and previous roles prior to his current position at Manhattan Scientifics, Inc. is not provided in the available source data. His professional credentials and detailed experience leading up to his role as CEO remain undisclosed within the provided information.
Track Record: Unknown. Specific key achievements, strategic decisions, or company milestones directly attributable to Emmanuel Tsoupanarias's leadership at Manhattan Scientifics, Inc. are not detailed in the provided source data. The available information does not specify his track record in successfully guiding the company's technology incubation or commercialization efforts.
MHTX OTC Market Information
Manhattan Scientifics, Inc. trades on the OTC Other tier, which represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies are not required to meet minimum financial standards or adhere to strict reporting requirements. This tier typically includes companies with limited public information, distressed financials, or those that are not current in their disclosures. This contrasts sharply with NYSE and NASDAQ, which demand rigorous financial reporting, corporate governance, and minimum share price/market capitalization for listing, providing investors with greater transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for low trading volume and illiquidity, making shares difficult to trade.
- Increased susceptibility to market manipulation due to less transparency.
- Difficulty in obtaining reliable financial information and company updates.
- Higher volatility and potential for significant price fluctuations.
- Verify the company's current financial statements and disclosure status, if available.
- Research any recent news, press releases, or corporate actions from official sources.
- Assess the commercial viability and market potential of its core technologies.
- Investigate the backgrounds and track records of management and key personnel.
- Understand the company's funding strategy and capital requirements for commercialization.
- Evaluate the intellectual property portfolio and its protection.
- Consult with a financial advisor experienced in OTC markets.
- Clear and consistent communication of business strategy and progress.
- Demonstrable progress in technology development or commercialization.
- Formation of credible strategic partnerships or licensing agreements.
- Adherence to any voluntary disclosure standards, even if not mandated.
- Presence of a functional website with updated company information.
Manhattan Scientifics, Inc. Healthcare Stock: Key Questions Answered
How does Manhattan Scientifics, Inc. navigate the regulatory landscape for its nanomedicine technologies?
Manhattan Scientifics, Inc. operates within the highly regulated healthcare sector, where its nanomedicine technologies would be subject to stringent regulatory approval processes, primarily by the FDA in the United States. While the provided data does not detail specific regulatory track records or pending approvals, the company's success in commercializing its innovations will heavily depend on its ability to meet these complex requirements. As an innovation hub, MHTX would likely engage in strategic collaborations or leverage expert consultants to guide its incubated technologies through preclinical testing, clinical trials, and the various stages of regulatory submission, ensuring compliance with safety and efficacy standards for medical devices or drug-device combinations.
What is Manhattan Scientifics, Inc.'s strategy for commercializing its early-stage nanotechnology portfolio?
Manhattan Scientifics, Inc.'s strategy for commercializing its early-stage nanotechnology portfolio centers on its role as a technology incubator. The company focuses on identifying and developing potentially disruptive technologies in nanotechnology and nanomedicine, aiming to bring them to market. Given its lean operational structure, this likely involves a multi-faceted approach, including securing strategic partnerships with larger pharmaceutical or medical device companies that possess the resources for manufacturing, distribution, and extensive market penetration. Additionally, MHTX may pursue licensing agreements for its intellectual property or consider spinning off successful ventures, thereby generating revenue without requiring significant direct operational investment in large-scale commercialization efforts itself. The emphasis is on leveraging external capabilities to bridge the gap between innovation and market introduction.
What are the implications of Manhattan Scientifics, Inc. being listed on the OTC Other market?
Manhattan Scientifics, Inc.'s listing on the OTC Other market carries several significant implications for investors. This tier is characterized by minimal regulatory oversight and disclosure requirements compared to major exchanges like the NYSE or NASDAQ. Consequently, investors may face challenges in accessing comprehensive and timely financial information, leading to reduced transparency. The OTC Other market typically experiences lower trading volumes and wider bid-ask spreads, which can result in significant liquidity issues, making it difficult to buy or sell shares efficiently. This environment often contributes to higher price volatility and increased susceptibility to market manipulation, posing substantial risks for investors seeking to engage with MHTX stock.
What are the key factors to evaluate for MHTX?
Manhattan Scientifics, Inc. (MHTX) holds an AI score of 46/100 (low). Not financial advice.
How frequently does MHTX data refresh on this page?
MHTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MHTX's recent stock price performance?
Manhattan Scientifics, Inc. (MHTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on high-growth nanotechnology and nanomedicine sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MHTX overvalued or undervalued right now?
Valuing Manhattan Scientifics, Inc. (MHTX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MHTX?
Before investing in Manhattan Scientifics, Inc. (MHTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited specific project details available for growth opportunities and CEO track record.
- Competitors section is empty as no peer tickers were provided in source data.
- FAQ answers are constructed based on the company's stated focus areas and industry context due to limited specific operational details.